Zogenix, Inc. (NASDAQ:ZGNX) Director Roger Hawley sold 35,000 shares of the business’s stock in a transaction that occurred on Tuesday, March 13th. The shares were sold at an average price of $44.71, for a total value of $1,564,850.00. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink.
Shares of Zogenix, Inc. (ZGNX) remained flat at $$44.50 during trading hours on Wednesday. 211,756 shares of the company’s stock were exchanged, compared to its average volume of 602,247. Zogenix, Inc. has a one year low of $10.00 and a one year high of $45.85. The stock has a market capitalization of $1,530.00, a P/E ratio of -12.57 and a beta of 1.57.
Zogenix (NASDAQ:ZGNX) last announced its quarterly earnings results on Tuesday, March 6th. The company reported ($1.14) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.97) by ($0.17). Zogenix had a negative net margin of 309.76% and a negative return on equity of 81.65%. During the same period in the prior year, the firm earned ($0.95) earnings per share. sell-side analysts anticipate that Zogenix, Inc. will post -3.12 earnings per share for the current year.
Large investors have recently made changes to their positions in the business. Voya Investment Management LLC grew its position in Zogenix by 13.5% in the second quarter. Voya Investment Management LLC now owns 14,147 shares of the company’s stock valued at $205,000 after acquiring an additional 1,686 shares during the period. Cubist Systematic Strategies LLC bought a new stake in Zogenix in the third quarter valued at $226,000. Sterling Capital Management LLC acquired a new position in Zogenix in the third quarter worth $237,000. Teacher Retirement System of Texas acquired a new position in Zogenix in the fourth quarter worth $409,000. Finally, Raymond James & Associates acquired a new position in Zogenix in the fourth quarter worth $460,000.
ILLEGAL ACTIVITY NOTICE: This piece was reported by American Banking News and is the sole property of of American Banking News. If you are accessing this piece on another publication, it was copied illegally and republished in violation of U.S. and international copyright & trademark law. The legal version of this piece can be viewed at https://www.americanbankingnews.com/2018/03/14/zogenix-inc-zgnx-director-sells-1564850-00-in-stock.html.
Zogenix Company Profile
Zogenix, Inc is a pharmaceutical company engaged in developing and commercializing central nervous system (CNS) therapies that address specific clinical needs for people living with orphan and other CNS disorders. Its primary area of therapeutic focus is epilepsy and related seizure disorders. Its lead product candidate, ZX008, is a low-dose fenfluramine for the treatment of seizures associated with Dravet syndrome.
Receive News & Ratings for Zogenix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zogenix and related companies with MarketBeat.com's FREE daily email newsletter.